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Kidney cancers are common neoplasms; more than 
300,000 new patients are diagnosed worldwide each 
year1. Most renal cancers arise from the epithelium of 
the renal proximal tubule and are sporadic. Renal cell 
carcinomas (RCCs) are best treated by resection; how-
ever, early diagnosis is difficult and metastases are often 
present before the primary tumour is detected2. As with 
all cancers, researchers hope that the rapidly increasing 
understanding of the molecular biology of tumour for-
mation and progression will provide the opportunity to 
develop new therapeutics and facilitate early diagnosis.
Loss of epigenetic regulation is clearly central to the 
development of renal tumours3–5. In the past 10 years, 
individual research groups and large consortia have 
used high-density microarrays that can identify sin-
gle 5’—C—phosphate—G—3’ (CpG) dinucleotides 
throughout the genome to determine DNA regions 
that are frequently methylated in tumours. Most of this 
work has focused on promoter region methylation and 
the associated control of gene expression4–9; however, 
the involvement of DNA methylation in RCC is more 
complex than first anticipated. Studies on the epigenetic 
regulation of other regulatory elements such as distal 
gene enhancers and repressors are now ongoing. The 
development of new microarrays with enhancer-spe-
cific probes and the increasingly affordable methods of 
methylation-specific genome-wide sequencing made 
such studies possible10.
In addition to DNA methylation, microRNAs (mi -
RNAs) also clearly influence RCC development. Studies 
using miRNA-specific microarrays and RNA sequenc-
ing technologies showed that these small RNA molecules 
have a central role in the normal physiology of renal 
cells, and their dysregulation is common in a wide range 
of RCCs. The number of experimentally validated, phys-
iologically relevant mi RNAs increases every year and 
evidence suggests that thousands of functional mi RNAs 
are still to be identified11. Although their importance is 
clear, many questions regarding the interplay between 
these noncoding RNAs, mRNAs and proteins during 
normal cellular physiology and cancer development 
remain to be elucidated.
RCC was one of the first tumour types for which 
concerted efforts were made to use massively parallel 
sequencing, at the time (7 years ago) a newly developed 
technique, to determine mutations in protein-coding 
regions (exome sequencing) on large numbers of indi-
vidual tumours12–14. These studies produced surprising 
results. Previous attempts to identify key, frequent muta-
tions in RCC had failed to yield much beyond the well-es-
tablished mutations in VHL15. The exome-sequencing 
projects identified common mutations in genes encoding 
histone-modifying proteins. Thus, key driving mutations 
in RCC can influence the epigenetic control of genome-
wide gene expression in renal cells. In the past 3 years, the 
Cancer Genome Atlas (TCGA) project consortium has 
published multiplatform analyses of large-scale cohorts 
of renal cancers4,5. These studies confirmed the frequent 
occurrence of histone modifying protein mutations 
in RCC and attempted to integrate these findings with 
global methylation and gene expression analysis.
Epigenetic control of gene expression through meth-
ylation of promoters and other regulatory elements, 
regulation of chromatin via histone modification, and 
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microRNAs
Small, noncoding RNAs that 
regulate gene expression 
post-transcriptionally by 
targeting specific mRNAs for 
inhibition or degradation 
through complimentary base 
pairing.
The epigenetic landscape  
of renal cancer
Mark R. Morris1 and Farida Latif2
Abstract | The majority of kidney cancers are associated with mutations in the von Hippel-Lindau 
gene and a small proportion are associated with infrequent mutations in other well characterized 
tumour-suppressor genes. In the past 15 years, efforts to uncover other key genes involved in 
renal cancer have identified many genes that are dysregulated or silenced via epigenetic 
mechanisms, mainly through methylation of promoter CpG islands or dysregulation of specific 
microRNAs. In addition, the advent of next-generation sequencing has led to the identification of 
several novel genes that are mutated in renal cancer, such as PBRM1, BAP1 and SETD2, which are 
all involved in histone modification and nucleosome and chromatin remodelling. In this Review, 
we discuss how altered DNA methylation, microRNA dysregulation and mutations in 
histone-modifying enzymes disrupt cellular pathways in renal cancers.
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Condensed chromatin
Regions of chromatin where 
nucleosomes are closely 
packed together preventing 
transcription.
Relaxed chromatin
Regions of the chromatin 
where nucleosomes vacate 
promoter regions allowing 
access to transcription factors 
and the transcriptional 
machinery.
CpG islands
Region of DNA with a high 
frequency of 5’–C–
phosphate–G–3’ (CpG) 
dinucleotides. These regions 
are frequent around 
transcriptional start sites.
miRNA-mediated control of protein production, are 
clearly central to normal cell function and their dysregu-
lation can lead to the development of renal cancers. How 
these pathways interact and are involved in RCC devel-
opment and progression remains unclear. This Review 
discusses epigenetic aberrations in renal cancer and their 
consequences on known and novel cellular pathways.
Epidemiology and genetics of renal cancer
RCCs include clear cell (cc)RCC (~70% of RCCs), pap-
illary (p)RCC (10–15% of RCCs), and chromophobe 
(ch)RCC (~5% of Rccs)16. Renal cancer usually occurs 
in adults but it can also affect children. The predomi-
nant form of childhood kidney cancer, Wilms tumour 
(~1 in 10,000 children), has a developmental origin. 
These tumours are associated with high incidences of 
additional developmental abnormalities17.
Unlike many other tumours, inactivating mutations 
of the tumour suppressor genes TP53 and RB1 are not 
frequent in renal cancers. TP53 is mutated in 11% and 
RB1 in <1% of all kidney cancers, whereas another 
known tumour-suppressor, CDKN2A, is mutated in 10% 
of patients with RCC18.
Somatic inactivation of VHL, which was originally 
identified in the hereditary cancer syndrome von Hippel-
Lindau (VHL) disease19, is very common in ccRCC (~52% 
of patients)4. The majority of the inactivating events are 
point mutations4,15,20,21. The VHL disease tumour suppres-
sor protein (pVHL) has multiple functions22, and is best 
known as a regulator of oxygen and energy sensing via 
the targeted degradation of the hypoxia-inducible factors 
(HIF) 1 and HIF2 (REFS 23–27) [Au: Refs OK?]. pVHL 
also regulates key cellular processes including glucose 
uptake and metabolism, angiogenesis, pH homeostasis, 
chemotaxis, proliferation and survival, apoptosis, tran-
scription regulation and cellular senescence through 
both HIF-dependent and HIF-independent mechanisms22 
(FIG. 1). Many of these key cellular processes can be affected 
by altered epigenetic regulation.
Non-hereditary pRCC can be subcategorised into 
pRCC type 1 and pRCC type 2 on the basis of his-
tology and molecular profiles5,16. The most common 
genetic aberrations in type  1 pRCC tumours are 
activating mutations of MET, which are found in 
~15% of tumours5,28. The most common mutations 
in type 2 pRCC affect CDKN2A (~8% of tumours)5. 
Mutations in FH, which encodes a citric acid cycle 
protein, cause the hereditary leiomyomatosis and 
RCC syndrome, which confers predisposition to 
type 2 pRCC29. FH is also mutated in sporadic pRCC at 
low frequencies5,30. Mutations in SDHB, which encodes 
iron-sulphur subunit of complex II, a component of the 
enzyme that converts succinate to fumarate in the citric 
acid cycle, are associated with familial RCC31–33. The 
principal mechanism that drives tumour formation 
following loss of FH or SDH is the stabilization of HIF, 
irrespective of the status of VHL34 (FIG. 1).
chRCCs arise from cells in the distal convoluted 
tubule of the nephron, whereas ccRCCs arise from cells 
in the proximal convoluted tubule; this difference in ori-
gin might explain the marked differences in the genetic 
and epigenetic makeup of these tumours. The most fre-
quently mutated genes in somatic chRCC are TP53 (32% 
of tumours) and PTEN (9% of tumours)28,35.
Wilms tumours are often associated with develop-
mental syndromes such as Wilms tumour, aniridia, gen-
itourinary abnormalities, mental retardation (WAGR) 
syndrome, and with deletions of chromosome 1136. Only 
around one-third of Wilms tumours have mutations in 
WT1 or PAX6 (two genes that are often encompassed in 
chromosome 11 deletions) or in other known tumour 
suppressor genes such as TP53, WTX or CTNNB1 
(REF. 37). Since 2012, studies have shown that mutations 
in genes that encode key components of the microRNA 
synthesis pathway (DICER1 and DROSHA) or mutations 
in a component of the RNA exosome complex (DIS3L2) 
are frequent in sporadic Wilms tumours38–40, indicating 
the importance of epigenetic regulation in the formation 
of these developmental tumours.
Epigenetics: basic principles
The availability of transcription factors, both via their 
presence within a cell and the accessibility of their target 
sequences in the genome, is essential to orchestrate gene 
expression. Chromatin states dictate genome accessibil-
ity; condensed chromatin prevents access of the transcrip-
tional machinery to the naked DNA, whereas relaxed 
chromatin allows access (FIG. 2). The localized levels of 
chromatin condensation are regulated by a complex 
network of histone-modifying proteins, such as his-
tone acetyltransferases (HATs) and histone deacetylases 
(HDACs), which determine the transcriptional activ-
ity of DNA by adding and removing methyl and acetyl 
groups from specific amino acids on histones41 (FIG. 2a,b). 
The addition of a methyl group to DNA cytosines within 
CpG islands can recruit HDACs and chromatin remod-
elling complexes[Au:OK?] to induce chromatin con-
densation and thus, gene silencing42 (FIG. 2b,c). Gene 
expression can also be regulated via control of the final 
protein concentration through post-transcriptional (but 
pre-translational) regulation of expression via the action 
of mi RNAs43 and other noncoding RNAs, which were 
considered to be non-functional until recently44.
Key points
• The most common mutations in renal cancers occur in the VHL gene; they disrupt 
many cellular pathways, notably those involved in the hypoxic response
• Other common mutations affect genes encoding proteins involved in histone 
modification and chromatin remodelling; mutations of these epigenetic modifier 
genes influence genome-wide gene expression
• Many key pathways involved in physiological renal cell function are disrupted by 
inappropriate silencing of component genes through methylation of CpG regions in 
promoters; these disruptions contribute to renal cancer development
• Alteration of the expression of microRNAs (mi RNAs) in renal cancers contributes to 
the disruption of important cellular networks
• In Wilms tumour, a common childhood renal cancer, miRNA maturation and 
degradation are often disrupted via mutations of key components of the miRNA 
biogenesis pathway
• Epigenetically disrupted genes in renal cancers are good candidate targets for the 
development of robust prognostic and diagnostic tools and novel therapeutics
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• SWI2/SNF2Expression levels altered
epigenetically in renal cancers
CpG island methylator 
phenotype
(CIMP). Tumour phenotype 
that is characterized by 
widespread and elevated levels 
of CpG island methylation. This 
phenotype represents a 
clinically and aetiologically 
distinct group [Au:OK?].
DNA and histone modifications and miRNA-me-
diated pathways are the major epigenetic regulatory 
mechanisms of gene expression. These processes do not 
change the genomic sequence of a cell but they can be 
inherited by daughter cells following cell division. These 
mechanisms are prone to error, often as a consequence 
of mutations or changes in the expression levels of the 
genes that encode the complex regulators45. As will be 
discussed below, these epigenetic dysregulations are 
characteristic of many renal tumours.
DNA methylation in renal cancer
In mammalian genomes methylation takes place pre-
dominantly at the cytosine bases that are located on 
the 5ʹ side of a guanosine (5 methylcytosine; 5 mC) in a 
CpG dinucleotide46,47. In the past 15 years, most research 
has focused on identifying changes in the methylation 
patterns of CpG-rich islands near or in gene promoters, 
which are clearly directly linked to gene silencing48,49. 
Nevertheless, many other genomic regions also have 
differential (tissue-specific), or aberrant (cancer) CpG 
methylation patterns50–54. Here, we will discuss the 
well-defined relationship between tumour specific CpG 
island methylation and gene silencing.
Promoter methylation
The first cancer-specific epigenetic abnormality identi-
fied was a genome-wide reduction in CpG methylation55. 
This global hypomethylation results in genomic insta-
bility that drives tumour formation56,57. In addition to 
global hypomethylation, tumour genomes undergo 
evolutionary selective pressure, which results in tumour 
suppressor gene silencing through localized promoter 
hypermethylation. The RB1 tumour suppressor was the 
first gene to be identified as silenced in tumours by this 
mechanism58. Many key tumour suppressor genes such 
as CDKN2A, TP53, MLH1 and CDH1 are also com-
monly inactivated in cancer by promoter methylation59.
In ~20% of ccRCC4,60 and ~7% of pRCC5, a high per-
centage of CpG islands are methylated. These tumours, 
which have a CpG island methylator phenotype (CIMP)61 
are aggressive and have increased glycolytic activity. 
Moreover, CIMP pRCC tumours are associated with 
poor overall survival5. The presence of methyl groups 
in specific DNA regions depends on DNA methyltras-
ferase (DNMT) 1, DNMT3A and DNMT3B, which are 
commonly overexpressed in cancers62. These enzymes 
and other methyl-CpG-binding proteins, such as 
MBD2, MBD3 and MeCP2, recruit HDACs and other 
histone-modifying proteins to the methylated promoter 
region62,63, which deacetylates histones 3 and 4 and 
induces chromatin condensation and gene silencing64.
5 mC can be oxidised to 5-hydroxylmethylcytosine 
(5hmC) by members of the methylcytosine dioxy-
genase ten eleven translocation (TET) protein family 
(TET1, TET2 and TET3)65–67. Many differentiated tissues 
Figure 1 | Involvement of pVHL in cellular physiology and RCC. The von Hippel-Lindau disease tumour suppressor 
protein (pVHL) regulates numerous cellular processes principally through the controlled degrad tion of hypoxia inducible 
factor (HIF). Hydroxylation of HIF by hypoxia-inducible factor prolyl hydroxylase 2 (PHD2), enables it to bind to pVHL and be 
targeted for degradation. This hydroxylation can be inhibited by the accumulation of succinate or fumarate as a 
consequence of mutations in the genes that encode succinate dehydrogenase (SDH) or fumarate hydrogenase (FH). pVHL 
also controls cell physiology through multiple HIF-independent mechanisms. These processes are also frequently 
dysregulated by the epigenetic silencing of regulators, changes in microRNA expression or mutations in chromatin 
remodelling proteins. ADM, adrenomedullin; BNIP3, BCL2/adenovirus E1B 19 kDa interacting protein 3; CA9, carbonic 
anhydrase 9; SDF-1, stromal cell-derived factor 1, also known as C-X-C motif chemokine ligand 12; EGFR, epithelial growth 
factor receptor; EMT, epithelial-to-mesenchymal transition; GLUT-1,3, glucose transporter type 1,3; HK II, hexokinase 2; 
NFκβ, nuclear factor κβ; PDGF, platelet-derived growth factor; PDH, pyruvate dehydrogenase; PRP 2, primer recognition 
protein 2, also known as phosphoglycerate kinase 1 (PGK1); RB, retinoblastoma protein; RNA Pol II, RNA polymerase II; RNA 
pSP1, specificity protein 1 transcription factor; SWI2/SNF, switch/sucrose non-fermentable ATPase (also called transcription 
activator BRG1 in humans); TGFR-1, transforming growth factor receptor; VEGF, vascular endothelial growth factor.
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accumulate high levels of 5hmC, which might be unique 
epigenetic marks and could regulate gene expression68. 
Genome-wide 5hmC levels are markedly reduced in 
ccRCC tissue compared to adjacent, non-malignant tis-
sue69. The precise mechanism of 5hmC loss and its role 
in malignancy are yet to be elucidated but this epigenetic 
mark might be a useful biomarker for ccRCC. The pre-
cise function of 5hmC and its signal transduction are 
also not yet known; however, the accumulation of 5hmC 
upstream of regulatory gene regions suggests a role for 
this modification in transcriptional regulation70.
Frequently dysregulated pathways
WNT–β‑catenin, MET and SLIT‑2–ROBO1 pathways. 
The proto-oncogene CTNNB1, which encodes β-cat-
enin, is located on chromosome 3p (3p22.1), which is 
often deleted in RCC and includes several other genes 
that carry point mutations or are silenced by promoter 
methylation in RCC and other cancers4,71[Au: Refs OK?]. 
β-Catenin is the downstream target of the Wnt pathway, 
which promotes the expression of tumourigenesis-in-
ducing proteins such as myc proto-oncogene protein 
(c-MYC) and cyclin D1 (REF. 72). In the absence of binding 
of WNT to members of the Frizzled (FZ) receptor fam-
ily or following the binding of slit homologue 2 protein 
(SLIT-2) to roundabout guidance receptor 1 (ROBO1), 
glycogen synthase kinase-3 β (GSK-3β) phosphorylates 
β-catenin. This phosphorylation primes β-catenin for 
ubiquitylation by jade family PHD finger 1 (JADE-1), 
a process that depends on the binding of JADE-1 to 
pVHL73. Indeed, the degradation of β-catenin is one of the 
key HIF-independent functions of pVHL73. The binding 
of WNT to FZ, low-density lipoprotein receptor-related 
protein (LRP) 5 and LRP-6 recruits GSK-3β, leading to 
the accumulation of β-catenin and its translocation to the 
nucleus. In the nucleus, β-catenin acts as a co-activator for 
Wnt-responsive genes such as c‑Myc and cyclin D1, which 
promote proliferation, survival and invasion72.
The Wnt/β-catenin pathway is frequently disrupted 
in RCC by promoter methylation of key pathway reg-
ulators (FIG. 3a), and unregulated β-catenin activation 
increases the tumourgenicity of renal cells74. In addition, 
VHL is inactivated in ~11–30% of ccRCC and pRCC by 
promoter methylation75–77 or by loss of chromosome 3. 
In the absence of pVHL, β-catenin can be targeted for 
degradation by the E3 ligase F-box/WD repeat-contain-
ing protein 1A (β-TrCP, also called β-transducin repeat 
containing protein)72,73,78. This process is often impaired 
in RCC owing to the inactivation of several Wnt pathway 
inhibitors by promoter methylation.
Two classes of inhibitor proteins regulate Wnt sig-
nalling: the secreted frizzled-related proteins (SFRPs), 
which bind directly to WNT and prevent it from bind-
ing to FZ, and the Dickkopf-related proteins (DKK), 
which bind to the LRP-5 and LRP-6 component of the 
WNT receptor complex. In addition, insulin-like growth 
factor-binding proteins (IGFBP) 1, 2, 4 and 6 bind to 
LRP-5, LRP-6 and FZ, which inhibits their activation 
by WNT79 (FIG. 3a). SFRP1 (47%), SFRP2 (53%), SFRP4 
(53%), SFRP5 (57%), WIF1 (73%) and DKK1 (44%), 
DKK2 (58%) and DKK3 (50%) are frequently meth-
ylated in RCC3. Loss of expression of these inhibitory 
proteins in RCC results in the accumulation of β-cat-
enin and upregualtion of its target genes80–84. IGFBP1 is 
also frequently silenced by methylation in ccRCC (35% 
of tumours) and pRCC (20% of tumours)85. Moreover, 
analysis of data generated by the TCGA Kidney Renal 
Clear Cell Carcinoma (KIRC) project identified SFRP1 
methylation as marker of poor patient survival86.
In RCC, 20% and 25% of tumours have reduced 
expression levels and associated promoter methyla-
tion of ROBO1 and SLIT‑2, respectively87,88. SLIT-2 and 
hepatocyte growth factor (HGF), and their respective 
Figure 2 | Histone acetylation regulates gene expression. a | Histon  
acetyltransferases (HAT) acetylate lysine tails; these marks keep the chromatin in an 
decondensed state, enabling the access of transcription factors (TF) and polymerases (Pol 
II) to the gene promoters. Proteins such as histone-lysine N-methyltransferase SETD2 and 
histone demethylase UTX, which are encoded by SETD2 and KDM6C (genes that are 
mutated in renal cancers), also maintain other open chromatin marks by removal (UTX) or 
addition (SETD2) of methyl groups to specific lysines. b | Following CpG methylation, 
methyl-CpG-binding domain proteins (MBD) bind to the methylated DNA and recruit 
histone deacetylases (HDAC), which remove acetyl groups. Additionally, the 
lysine-specific demethylase 5C (JARID1C) encoded by KDM5C, which is mutated in renal 
cancers, removes specific methyl groups in transcriptionally silenced regions of the 
genome. c | Following deacetylation (and other histone modifications) chromatin 
remodelling complexes are recruited to the region; these complexes bring nucleosomes 
together, causing DNA condensation and thus preventing access of TFs or polymerases 
to promoters.
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receptors ROBO1 and MET (also known as HGF recep-
tor)89, regulate β-catenin levels. SLIT-2 binds to ROBO1, 
which activates GSK-3β and results in the degrada-
tion of free cytoplasmic β-catenin90. Activation of the 
SLIT-2–ROBO1 pathway also stabilizes the interaction 
of β-catenin and E-cadherin, which positively regulates 
cell adhesion91 and inhibits CDC42, which induces cell 
adhesion by potentiating RAC1 and inhibiting HGF–
MET-induced motility and invasion92 (FIG. 3b).
Somatic mutations of RASSF1, which maps to 
3p21.31 —a region of frequent allele loss in many 
cancers93 — are rare in RCC; however, silencing by 
biallelic promoter methylation or by methylation 
after loss of chromosome 3 are common as RASSF1 
is methylated in 29–91% of tumours3,94–96. Ras associ-
ation domain-containing protein 1, which is encoded 
by RASSF1, functions as a tumour suppressor by reg-
ulating metaphase and G1/S phase cyclin degradation 
Figure 3 | Multiple pathways are epigenetically dysregulated in renal 
cancer. a | The binding of Wnt to the frizzled receptor (FZ) and LRP5 or LRP6 
inhibits GSK-3β, which prevents the phosphorylation of β-catenin. 
Unphosporylated β-catenin is translocated to the nucleus where it promotes 
the expression of proto-oncogenic targets such as cyclin D1 and c-MYC. 
c-MYC upregulates the expression of positive regulators of cell proliferation 
and glycolysis. The secreted frizzled proteins (SFRP) 1, 2, 4 and 5, Wnt 
inhibitor factor 1 (WIF1, which inhibit Wnt), Dickkopf (DKK) 1, 2 and 3 and 
insulin-like growth factor binding protein 1 (IGFBP1, which inhibits LRP5 and 
LRP6), are frequently downregulated by promoter methylation, resulting in 
upregulation of β-catenin targets. Von Hippel-Lindau disease tumour 
suppressor (pVHL) and jade family PHD finger protein 1 (JADE-1) target 
β-catenin for degradation by ubiquitylating it. Binding of slit homologue 2 
protein (SLIT-2) to roundabout guidance receptor 1 (ROBO1) activates 
GSK-3β and stabilizes the binding of β-catenin to E-cadherin. SLIT-2 and 
ROBO1 are silenced by promoter methylation in RCC. b | E-cadherin, a 
regulator of cell adhesion and maintenance of the epithelial phenotype, is 
frequently methylated in RCC. Tyrosine-protein kinase Met (MET, also known 
as hepatocyte growth factor receptor) is activated by HGF (hepatocyte 
growth factor), which is inhibited by kunitz-type protease inhibitor 2 (SPINT2, 
also called HAI-2). The expression of SPINT2 is frequently lost in papillary 
renal cell carcinoma (RCC) and clear cell RCC. MET expression can be 
downregulated by miR-206, which is frequently downregulated in RCC. Ras 
association domain-containing protein 1 (RASSF1) has dual 
tumour-suppressing functions: it inhibits GTPase HRas (H-RAS-1) signalling 
and inhibits the accumulation of cyclins A and D1. c | Binding of transforming 
growth factor β (TGFβ) to its receptor activates mothers against 
decapentaplegic homologue (SMAD) proteins, which upregulate the 
expression of transcriptional repressors including zinc finger protein SNAI1, 
zinc finger E-box-binding homeobox (ZEB) 1, and ZEB2. These proteins 
inhibit multiple targets and promote epithelial-to-mesenchymal transition 
(EMT) and the expression of several proteins such as E-cadherin. Fibrillin 2 
(FBN2), an extracellular matrix protein that is one of the most frequently 
silenced proteins by promoter methylation in RCC, prevents TGFβ from 
binding to its receptor and its silencing in RCC leads to ectopic activation of 
the TGFβ pathway.
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as well as activating apoptotic pathways in response 
to DNA damage via the ATM or JNK pathways96 
(FIG. 3b).
Activating mutations of MET are associated with 
hereditary pRCC97 and sporadic pRCC5,98 but they are 
rare in sporadic ccRCC4. MET is central to the control 
of several key tumourigenic processes such as cellular 
proliferation, metabolism and cell motility via the PI3K/
AKT/mTOR and the RAS/RAF pathways99. SPINT2 
encodes Kunitz-type protease inhibitor 2 (SPINT2, also 
called HAI-2), which inhibits HGF activator, a pro-
tein required for HGF-mediated activation of MET100 
(FIG. 3b). SPINT2 is frequently methylated and silenced 
in ccRCC (30%) and pRCC (45%)101. These findings 
suggest that MET-mediated signalling is commonly 
disrupted in RCC.
Cell adhesion and EMT. In renal cells, pVHL contrib-
utes to maintaining the expression of CDH1, which 
encodes E-cadherin, a protein required to preserve 
renal epithelial morphology102. Loss of pVHL causes 
HIF-induced expression of Zinc finger E-box-binding 
homeobox 2 (ZEB2, also called SIP1) and zinc finger 
protein SNAIl, which repress the expression of multiple 
target genes, including CDH1 (REFS 103,104). Reduced 
E-cadherin levels increase tumourigenicity and promote 
epithelial-to-mesenchymal transition (EMT)105. Multiple 
studies found that E-cadherin is silenced by CDH1 pro-
moter methylation in ccRCC and pRCC3.
FBN2, which encodes fibrillin-2, is frequently meth-
ylated in RCC, and loss of FBN2 expression in vitro is 
associated with increased tumourigenicity of RCC cells8. 
Analysis of data from the TCGA KIRC project suggests 
that FBN2 methylation is the most common epigenetic 
mark in RCC as it was present in 40–53% of the 200 
patients analysed, and FBN2 mutations are also fairly 
frequent (3% of patients)86. Fibrillin-2 can sequester 
transforming growth factor β (TGFβ) in the extracellular 
matrix and interrupt its downstream signalling pathway, 
which inhibits E-cadherin expression through SNAI1 
[Au: OK?], ZEB1 and ZEB2 (REFS 106,107) (FIG. 3c). This 
TGFβ-induced inhibition of E-cadherin expression 
results in enhanced tumourigenicity and EMT106,107.
Two studies showed that PCDH8, a second member 
of the cadherin family, is also silenced by methylation in 
ccRCC (19%−58%)8,86. This epigenetic mark correlated 
with poor patient survival86. Although the function of 
PCDH8 has yet to be elucidated, increasing evidence 
suggests that this class of adhesion molecules has impor-
tant roles in cell signalling, cell adhesion and mainte-
nance of the epithelial phenotype108.
In addition to the extracellular matrix protein 
fibrillin-2, four members of the collagen family are 
frequently downregulated or silenced in RCC by pro-
moter methylation: COL1A1, (65% in ccRCC and 40% 
in pRCC)85, COL1A2 (29% in ccRCC)109, COL14A1 
(44% in ccRCC)110 and COL15A1 (53% in ccRCC)110. 
LOXL1, which encodes lysyl oxidase homologue 1, an 
extracellular enzyme involved in crosslinking collagens 
and elastin111, is also methylated in 35% of patients with 
ccRCC110. How the loss of these proteins is involved in 
RCC development is unknown; however, extracellular 
matrix remodelling is clearly emerging as a process cen-
tral to malignancy and metastasis112.
Energy homeostasis. VHL, MET, FLCN, TSC1, TSC2, 
FH and SDH, which are commonly mutated in kidney 
cancer, are involved in the cellular response to meta-
bolic stress or nutrient stimulation113,114. Consequently, 
kidney cancer can be defined as a metabolic disease. 
As described above, some of these genes (VHL, SDHB 
and FLCN) are also silenced by promoter methylation, 
although somewhat infrequently3. In addition, the com-
plex signalling networks involved in metabolism are 
commonly altered in RCC owing to epigenetic silenc-
ing of component genes. Protein kinase AMP-activated 
catalytic subunit α1, a master regulator of cellular energy 
homeostasis encoded by AMPK, is a component of the 
MET–FLCN–mTOR signalling network115, which can 
be dysregulated by silencing of FLCN116,117 or SPINT2 
(REF. 101).
Other notable metabolic targets that are epigeneti-
cally dysregulated in RCC include CDO1 (REF. 118) and 
SLC16A3 (also known as MCT4)119. SLC16A3 encodes 
solute carrier family 16 member 3, a monocarboxy-
late transporter that is essential for transport of lactate 
across the plasma membrane, thus maintaining cellu-
lar pH and the appropriate progression of glycolysis119. 
Overexpression of SLC16A3 correlates with poor patient 
prognosis and is associated with lower promoter methyl-
ation in the tumour compared to less aggressive tumours 
and normal tissue119. CDO1, which is an essential mem-
ber of the taurine biosynthetic pathway, is involved in the 
oxidative stress response120,121. As in other types of malig-
nancies such as breast cancer122, colorectal cancer123 and 
prostate cancer124, methylation of the CDO1 promoter 
is associated with poor survival of patients with RCC118. 
[Au: OK?]
Other pathways. In addition to the signalling pathways 
outlined above, which are altered by the silencing of mul-
tiple genes in RCC, other pathways are affected by the 
silencing of genes such as APC, APAF1, BNC1, CASP8, 
CDKN2A, FHIT, GREM1, MGMT, TU3A and UCHL1 
(REFS 3–5,86). For some of these genes, whether and how 
the absence of the proteins that they encode is involved 
in RCC development is not yet clearly understood. In 
some cases, methylation-induced gene silencing is also 
likely to be a passenger event; however, the silencing of 
genes through methylation of their promoter in RCC 
clearly has a widespread influence on tumour progres-
sion, and often leads to the dysregulation of key cellular 
processes such as the cell cycle (CDKN2A, CDKN2B 
4,6,125), apoptosis (CASP8, DAPK126,127), genomic stability 
(MGMT3,125) and angiogenesis (TIMP3 (REFS 128–130)).
Non-promoter DNA methylation
Most methylation analyses have focused on CpG meth-
ylation at defined promoter regions directly adjacent to 
transcription start site. [Au: OK?] However, large-scale 
genome-wide analysis projects such as ENCODE131,132 
and FANTOM5 (REF. 133) showed that distant regulatory 
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enhancers also undergo CpG methylation. Enhancer 
methylation in RCC has been analysed at the genome 
scale, and one study in particular identified an enrich-
ment of aberrant enhancer methylation associated with 
networks involved in the cellular response to hypoxia134. 
This study also found that methylation of enhancers 
correlated with poor prognosis. Improved mapping of 
enhancer elements and the development of new methyl-
ation arrays that include probes for these regions135 have 
opened many avenues of investigation still to be explored 
in this field.
Histone modification in renal cancer
Basic principles
Nucleosomes are composed of approximately 146bp 
of DNA that are wrapped around an octamer com-
posed of two of each histone protein (H2A, H2B, H3 
and H4)136. Histones have many chemically modified 
amino acids; the lysine residues in the external ‘tails’ 
can be acetylated, methylated or ubiquitylated, serine 
residues can be phosphorylated and arginine residues 
can be methylated136. These modifications form the basis 
of ‘the histone code’ (REF. 137) and control the expression 
of associated genes131. Chromatin remodelling protein 
complexes (SWI/SNF and BAF-associated complexes) 
can be recruited to either condense chromatin and 
silence a gene region or decondense chromatin and ena-
ble gene expression according to the different histone 
marks. Chromatin remodelling is ATP-dependent and 
occurs through the physical movement or removal of 
nucleosomes138. PBRM1 encodes the chromatin-target-
ing subunit protein polybromo-1 (also called BAF180) 
of the SWI/SNF chromatin-remodelling complex139,140. 
This multimeric complex has essential roles in DNA 
repair, proliferation and differentiation141, and is consid-
ered a master regulator of gene expression as it associates 
with a large number of transcription factors4,141.
Histone modification in RCC
Until a few years ago, renal tumours were considered to 
be somewhat unusual as they had a fairly low frequency 
of gene mutation, with the exception of mutations in 
VHL. The application of parallel, second-generation 
sequencing in large-scale projects identified novel and 
frequent mutations in chromatin remodelling genes such 
as PBRM1, BAP1, SETD2 (although their methylation is 
uncommon142), KDM5A (also known as JARID1C) and 
KDM6A (also known as UTX), which both encode his-
tone demethylases 4,12–14,143.
PBRM1. PBRM1 is frequently mutated in RCC (41% 
in ccRCC14) and it is likely to be a tumour suppressor 
gene. Most PBRM1 mutations are inactivating and 
loss of expression is associated with an increase in cell 
proliferation and migration14, whereas its reintroduc-
tion reduces cell proliferation and is associated with 
G1 cell cycle arrest induced by an increase in p21CIP1 
(REFS 144,145). Reports of PBRM1 expression levels in 
RCC and of its association with poor patient survival are 
contradictory146,147. The precise mechanisms that under-
lie the oncogenic contribution of PBRM1 mutations in 
RCC remain to be clarified; however, in addition to 
its role in regulating genes that control proliferation, 
such as p21CIP1, PBRM1 also regulates the expression 
of cell-adhesion and cell-signalling molecules such as 
E-cadherin148–150 (and as such, the subcellular distri-
bution of β-catenin) as well as sister chromatid cohe-
sion151. Thus, correct expression of PBRM1 is likely to 
have important roles in pathways that are frequently 
dysregulated in cancer and in maintenance of genomic 
integrity, which is a barrier to tumourigenicity152.
SETD2. SETD2 and its splice variants encode enzymes 
that depose trimethylated histone H3 lysine 36 marks153. 
SETD2 is mutated in non-renal tumours154–156, and is 
biallelically inactivated in 3–12% of RCCs4,12,13,143,157. 
SETD2 mutations are associated with genome-wide loss 
of non-promoter DNA methylation in RCC4, and loss 
of SETD2 is sufficient to reduce the levels of the histone 
mark H3K36Me3 across the genome158. This histone 
methylation is associated with open heterochroma-
tin and reduced CpG methylation159,158, and changes 
in heterochromatin structure (such as nucleosome 
rearrangement) can alter the accessibility of the spli-
ceosome machinery to genes and alter the expression 
of splice-variants. SETD2 mutations could, therefore, 
change the expression levels and functional structure of 
many genes160. H3K36Me3 is required for serine-protein 
kinase ATM and TP53-mediated DNA damage check-
point activation161 and the recruitment of the DNA 
mismatch repair protein Msh2 (also called hMutSα)162, 
suggesting that loss of SETD2 function combined with 
PBRM1 mutations could increase genomic instability 
and prevent correct cell-cycle checkpoint control. The 
potential importance of the tumour-supressing activity 
of SETD2 is supported by reduced survival in patients 
with tumours that harbour SETD2 mutations4,157.
KDM5C and KDM6A. The histone demethylases 
JARID1C and UTX, which are encoded by KDM5C and 
KDM6A, are mutated in ccRCC (7% and 1% of patients 
respectively) 4,12–15,143 and pRCC (1% and 4% of patients, 
respectively)5[Au: Refs OK?]. JARID1C removes methyl 
groups from lysine 4 of histone H3 (H3K4Me3) and 
UTX removes methyl groups from lysine 27 of histone 
H3 (H3K27Me3)163.
HIF induces the expression of JARID1C, which 
inhibits its target genes by removing H3K4Me3 — a 
known marker of actively transcribed chromatin164. 
Some of the genes inhibited by JARID1C are HIF-
responsive (such as IGFBP3, DNAJC12, and COL6A1)165, 
suggesting that in this context, JARID1C acts as a buffer 
by regulating the level of HIF targets. Uncontrolled 
upregulation of these HIF targets results in changes in 
normal cellular physiology, notably, cellular metabolism 
and angiogenic signalling166. A xenograft study showed 
that KDM5C knockdown in VHL−/− cell lines increased 
tumour growth, supporting the tumour-suppressor 
function of JARID1C165. The full array of genes targeted 
by JARID1C is unknown but, as H3K4Me3 is a common 
mark of transcriptional activity, this enzyme is suspected 
to influence the expression of a large number of genes.
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The H3K27Me3 histone mark is associated with 
repressed transcription164, suggesting that loss of func-
tional UTX in RCC might lead to pathological down-
regulation of numerous genes. This downregulation has 
been shown to occur in vitro12.The precise mechanism 
or relative contribution of these fairly rare mutations to 
the oncogenic process in the kidney is, however, yet to 
be elucidated.
BAP1. BAP1 encodes a deubiquitylating enzyme with 
multiple targets. This gene is mutated in up to 11% of 
patients with ccRCC143,167,168 and 3% of patients with 
pRCC5. BAP1 is associated with multiprotein complexes 
that include breast cancer type 1 susceptibility protein 
(BRCA1) and BRCA1-associated RING domain protein 
1 (BARD1). These complexes regulate key cellular path-
ways including DNA damage response, cell cycle con-
trol and apoptosis169. Binding of BAP1 to BRCA1 and 
BARD1 prevents them from ubiquitylating histone H2A 
lysine 119 (H2A119K)169. This ubiquitylation is essen-
tial for the tumour-suppressing function of BRCA1 in 
response to DNA damage, and for the radiation-induced 
loss [Au:OK?] of BAP1-sensitized cells170.
In addition to its essential role in the orchestrated reg-
ulation of the BRCA1-mediated DNA damage response, 
BAP1 directly deubiquinates H2A119K and binds to E2F 
family member transcription factors and E2F-responsive 
promoters. Loss of BAP1 reduces transcription of E2F 
targets and slows cell-cycle progression167,171. The fact 
that loss of BAP1 slows cell growth is initially coun-
terintuitive as it conflicts with its tumourigenic effect; 
however, loss of BAP1 also reduces the fidelity of the 
G1/S phase checkpoint, thus facilitating uncontrolled 
cell growth172.
Further work is required to elucidate the mechanisms 
by which BAP1 loss promotes RCC tumourigenesis; how-
ever, several studies showed that BAP1 loss is associated 
with high tumour grade167, high tumour stage173 and poor 
prognosis4,157,173,174. Of note, loss of BAP1 expression cor-
relates with mTORC1 activation167. Activation of the 
mTOR pathway is associated with aggressive tumours 
and, as described above, this pathway disrupted in hered-
itary and sporadic renal tumours by direct mutation or 
epigenetic silencing of pathway regulators (FIG. 3b).
mi RNAs in renal cancer
Approximately 3,000 human mi RNAs have been exper-
imentally validated as physiologically relevant thus 
far175. This number has risen year-on-year since the 
discovery of mi RNAs and is expected to continue to 
increase11, reflecting the physiological importance of 
these noncoding mRNAs. mRNAs (primary mi RNAs) 
are cleaved by ribonuclease 3, which is encoded by 
DROSHA, into a 60–70-nucleotide hairpin precursor 
miRNA (pre-miRNA)176, which is then exported to the 
cytoplasm where endoribonuclease DICER, another 
RNase III enzyme, processes it to the final mature 
22-nucleotide-long double-stranded miRNA176. The 
mature miRNA directs the miRNA-induced silencing 
complex (miRISC) to the target mRNA, which leads to 
its degradation176.
Dysregulation of both miRNA expression and pro-
cessing has a key influence on tumour formation176–178. In 
the past 10 years, screens of miRNA expression in RCC 
have shown widespread miRNA dysregulation179–181. Of 
note, more mi RNAs were downregulated or silenced in 
renal tumours than in normal tissue, and this downreg-
ulation or silencing [Au: OK?] was often associated with 
promoter methylation or copy number changes179,182–188. 
Many of these mi RNAs target components of networks 
that are dysregulated by mutations or promoter meth-
ylation. These networks include HIF target genes and 
members of the TGFβ signalling pathway.
Dysregulated cellular pathways
The VHL–HIF network. The two HIF proteins (HIF1α 
and HIF2α) have contradictory roles in renal tumour 
progression: HIF1α has tumour-suppressing activity, 
whereas HIF2α is oncogenic189–191. pVHL decreases 
HIF1α and HIF2α protein levels22 and induces the 
expression of miR-30c-2-3p and miR-30a-3p, which 
target HIF2α transcripts for degradation. Loss of pVHL, 
therefore, increases HIF1α and HIF2α protein levels 
and promotes HIF2α transcription through the loss of 
miR-30c-2-3p and miR-30a-3p192. Patients with RCC 
who have reduced levels of these mi RNAs have reduced 
survival192.
Both HIF1α and HIF2α upregulate the expression of 
miR-210 (REF. 193), which in turn targets HIF1α, thus 
amplifying the oncogenic imbalance between HIF1α and 
HIF2α194,195. miR-210 also targets several genes involved 
in the hypoxic response, such as genes with roles in the 
DNA damage response (RAD52), angiogenesis (EFNA3, 
PTP1B), cell cycle (PLK1, CDC25B, Cyclin F, BUB1B, 
FAM83D, E2F2) and metabolism (SDHD, ISCU1/2)194 
(FIG. 4). [Au: OK?]
Vascular endothelial growth factor (VEGF) is a reg-
ulator of angiogenesis and a key transcriptional target of 
HIF. Protein levels of VEGF are controlled by miR-206 
and miR-106a-5p, which are frequently downregulated 
in ccRCC196. The VEGF receptor can also be upregu-
lated if the levels of mi RNAs 206, 106-5a, 216b, 3065-5p, 
335-5p or 3065- 5p196 are decreased. The dysregulation of 
multiple mi RNAs is a common hallmark of cancers, and 
is often associated with genome-wide methylation and 
chromatin pattern changes or mutations in miRNA-pro-
cessing proteins43,180,197. High levels of VEGF, which can 
be secreted by RCC cells, promote the development of 
new blood vessels that associate with the tumour, and 
can also act in an autocrine manner to increase tumour 
cell migration and invasiveness198.
TGFβ and EMT. The miR-200 family (which includes 
miR-141, 200a, 200b and 200c) is among the most fre-
quently downregulated group of mi RNAs in RCC199–203. 
This miRNA family and miR-30c are involved in the 
regulation of EMT199–203. Their expression can be inhib-
ited by TGFβ signalling, leading to reduced expression 
of ZEB1, ZEB2 and SIP1 (REFS 199,200,202), which tran-
scriptionally repress E-cadherin and induce EMT106,107 
(FIG. 3c). As discussed above, E-cadherin is essential to 
maintain epithelial identity and localizes β-catenin to 
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the cytoplasm. Therefore, loss of expression of these mi -
RNAs can contribute to EMT in the absence of external 
signals by indirectly reducing E-cadherin levels in the 
cell. In addition, a 2014 study showed that miR-141 sup-
pressed metastasis by targeting EphA2 transcripts, which 
reduced cell adhesion by dysregulating AKT, RAC1 and 
MMP2 pathways204.
MET and mTOR pathways. miR-206 is frequently down-
regulated in ccRCC196 and directly downregulates c‑MET 
and BCL2 transcripts in lung and rhabdomyosarcoma 
tumours205,206, suggesting that this mechanism might 
contribute to tumour progression in RCC. Phosphatase 
and tensin homologue (PTEN) inhibits PI3K-mediated 
phosphorylation of AKT and subsequent activation of 
mTORC1. PTEN is targeted by several mi RNAs, includ-
ing miR-221, miR-222, miR-22, miR-486, miR-21 and 
miR-23b-3p207,208. This inhibition of PTEN increases 
mTOR activity resulting in elevated levels of prolifera-
tion, invasiveness, and migration of RCC cells209. miR-
NA-mediated regulation of protein levels is an essential 
layer of control that acts on known molecular pathways 
and is crucial to maintain the intricacy of cell signalling 
required for normal cellular physiology.
Mechanisms of miRNA dysregulation
As with other tumour suppressors genes, individual 
mi RNAs are often silenced or downregulated in RCC 
by promoter methylation4,210–212 and have single nucle-
otide polymorphisms (SNPs). These SNPs alter the 
ability of mi RNAs to bind to target sequences and are 
associated with RCC susceptibility213,214. In addition, the 
genes encoding components of the miRNA biogenesis 
and processing pathways can also be mutated in RCC. 
Germ-line and somatic mutations in key components 
of the miRNA biogenesis and processing pathways are 
common in Wilms tumours. Mutations in DROSHA and 
its binding partner, DGCR8 (also known as PASHA), 
which processes mi RNAs, occur in approximately 12% 
and 8% of Wilms tumours, respectively18,38,39. DICER, the 
ribonuclease III enzyme responsible for the final mat-
uration of pre-mi RNAs, is mutated in ~4% of Wilms 
tumours18,38,39,215; however, mutations in these genes 
occur infrequently in adult, non-Wilms RCC4,5.
Loss of these processing enzymes results in wide-
spread, yet distinct patterns of mature miRNA 
expression. Of note, the expression of the LET-7 fam-
ily of tumour-suppressing mi RNAs is particularly 
impaired38,39. The LET-7 family comprises 12 members, 
the expression of which is coordinated during develop-
ment and high in differentiated cells216. LET-7 mi RNAs 
inhibit the expression of C‑MYC217 and RAS218, which 
are pro-proliferative proto-oncogenes; IGF1R, INSR, 
and IRS2, which positively regulate glucose metabolism 
and activate the PI3K/mTOR pathway219; and SAL14, 
Oct4, Sox2, Nanog and LIN28, which induce pluripo-
tency217,220. Thus, the LET-7 mi RNAs have a pivotal role 
in determining cell fate and ensuring appropriate cell 
differentiation. The post-transcriptional levels of LET-7 
mi RNAs are regulated by LIN28, which is overexpressed 
in multiple types of tumours including Wilms, and the 
expression of which correlates with tumour aggressive-
ness221. Moreover, LIN28 overexpression induces Wilms 
tumours in mice222.
LIN-28 targets LET-7 pre-mi RNAs for degradation 
by polyuridylating them at their 3ʹ end, which targets 
them for degradation by the DIS3-like exonuclease 
2 (DIS3L2)223,224 (FIG. 5). Mutations in DIS3L2 cause 
Perlman syndrome, a rare congenital overgrowth syn-
drome characterized by the development of Wilms 
tumours40. Loss of DIS3L2 results in an increase in 
polyuridylated LET-7 and the upregulation of many 
mRNAs223–225; however, the precise influence of DIS3L2 
loss on the levels or activity of mature LET-7 mi RNAs is 
yet to be clarified223,226. Mutations (exonic deletions) of 
DIS3L2 have been identified in 30% of sporadic Wilms 
tumour40. These findings highlight the importance of 
miRNA regulation in the development of tumours and 
the requirement for an appropriate balance of expression 
in the LIN-28–LET7 axis.
Clinical applications
Diagnosis
Early diagnosis of RCC can be challenging, with symp-
toms often presenting only late in disease progres-
sion. Ideally, tumours should be detected early, while 
they are still spatially confined. Epigenetic marks, in 
Figure 4 | microRNAs control the balanc  of
tumour-suppressor HIF1α and oncogenic HIF2. Loss of 
von Hippel-Lindau disease tumour suppressor protein 
(pVHL) upregulates the expression of hypoxia inducible 
factor (HIF) 1α and HIF2α and downregulates the 
expression of miR-30a-3p and miR-30c-2-3p, which are 
HIF2α inhibitors. This loss results in an imbalanced increase 
in the levels of proto-oncogenic HIF2α. This imbalance is 
reinforced by the HIF-depended upregulation of miR-210, 
which reduces HIF1α transcripts levels. miR-210 targets 
key proto-oncogenic pathways as part of the hypoxic 
response. Independently of HIF1α, high levels of HIF2α 
reduce cell adhesion and epithelial-to-mesenchymal 
transition (EMT) by inhibiting miR-30c, which results in 
increased expression levels of zinc finger protein SNAI2 
(also known as SLUG) and, consequently, reduced 
E-cadherin levels.
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particular DNA CpG methylation, offer great poten-
tial as a diagnostic and prognostic indicator of RCC 
development. The DNA assays to identify such marks 
are generally robust and promoter methylation is fairly 
uniform across the promoter region, which provides 
a clear advantage over targeted sequencing of candi-
date mutation sites. Moreover, tumours produce indi-
vidual cells that can be isolated in urine and plasma, 
along with cell-free DNA. Several studies have now 
shown that specific gene methylation patterns can 
be identified in urine and serum. Gene aberrations 
identified using such analyses include tumour-spe-
cific methylation of VHL, RASSF1, MGMT, GSTP1, 
p16INK4, p14ARF, APC, TIMP3, KILLIN, LINE‑1 
(REFS 227–231), SFRP1 and several other antagonists 
of the Wnt/β-catenin pathway232. The ability to identify 
altered methylation of genes such as VHL and RASSF1 
in urine and blood is promising as they are silenced 
early and frequently in tumour evolution, thus pro-
viding the potential for the development of an effective 
diagnostic screen.
Several studies have investigated the prognostic 
potential of DNA methylation in renal cancers in the 
past 10 years. Analysis of genome-wide epigenetic 
profiles of different renal tumour types has identified 
methylation signatures (epi-signatures) that can identify 
specific subtypes of RCC233.
Prognosis
Specific CpG island methylation profiles have been asso-
ciated with overall patient survival. For example, in a 
study of nearly 1,000 patients, the methylation of five 
CpG sites (associated with the genes PITX1, FOXE3, 
TWF2, EHBP1L1 and RIN1) were negatively associated 
with overall survival234.
The metastatic potential of the primary tumour is a 
key factor that can predict patient survival. Epigenetic 
changes, which depend on the type of treatment and 
the tissue-specific microenvironment, are likely to drive 
much of the metastatic process. Metastasising tumours 
undergo branched evolution at a genetic level, resulting 
in many cases where the metastasis is no longer genet-
ically identical to the primary tumour235,236; however, 
genome-wide methylation analyses have revealed that 
primary renal tumours and resulting metastases remain 
remarkably similar at the level of DNA methylation237. 
Persistent similarities between primary and metastatic 
tumours might present good opportunities for the devel-
opment of novel therapies. Whether specific epigenetic 
differences exist between primary tumours that readily 
metastasize and those that do not will be of great interest.
The heterogeneity of mutations within tumours, 
which results in different subclones that evolve differ-
ently, is a major obstacle to clinical translation235,236,238,239. 
Intratumour heterogeneity of DNA methylation might, 
however, not be as pronounced as intratumour hetero-
geneity of genomic changes. [Au: OK?] In the study that 
identified five CpG sites that are associated with poor 
survival234, the researchers also analysed the presence of 
these five CpG sites in three separate regions dissected 
from the same tumour. This analysis, which included 
tumours from 23 patients, found generally consistent 
methylation levels within individual tumours. These 
findings are consistent with the observation that primary 
and metastatic tumours remain epigenetically similar237.
Several studies have analysed the presence of multiple 
mi RNAs in serum from patients with RCC to provide 
prognostic information and identify renal-specific can-
cers240–242. The use of miRNA profiles to predict treat-
ment response has also been proposed and two studies 
have identified panels of mi RNAs that are associated 
with different responses to sunitinib, an FDA-approved 
treatment for RCC243,244.
Treatment development
The identification of mi RNAs that regulate multiple 
pathways central to renal tumour progression presents 
opportunities for the development of new therapeutic 
strategies, such as the reintroduction of tumour-sup-
pressing mi RNAs that are downregulated in RCC or 
the inhibition of oncogenic mi RNAs. Preclinical trials 
involving the delivery of miRNA mimics that replace the 
function of lost mi RNAs or of RNA oligonucleotides that 
act as decoy targets for oncogenic mi RNAs have shown 
promising results in several tumour types. [Au: Please 
reference] In vitro, mi RNAs have been extremely suc-
cessful at inducing cell cycle arrest, apoptosis and inhib-
iting invasion, whereas local delivery of mi RNAs in vivo 
can reduce tumour size245. However, many challenges 
Figure 5 | microRNA pathways dysregulated in Wilms tumo rs. The expression f the 
LET-7 family of micro RNAs (mi RNAs) is dysregulated in Wilms tumours via three 
mechanisms. a | Mutations in DGCR8 and DROSHA prevent processing of pri-mi RNAs 
(removal of poly-A tail and cap) and pre-miRNA formation. b | Mutations in DICER 
prevent the processing of LET-7 pre-miRNA into mature mi RNAs. c | Overexpression of 
protein lin-28 homologue A (LIN-28A) results in polyuridylation of pre-LET-7 mi RNAs and 
targeted degradation by the DIS3-like exonuclease 2 (hDIS3L2). hDIS3L2 is also 
commonly mutated in Wilms tumours, resulting in an accumulation of uridylated 
pre-LET-7 mi RNAs. Loss of LET-7 miRNA results in the dysregulation of multiple 
proto-oncogenic pathways. Pol II, RNA polymerase II.
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still need to be overcome before this type of molecu-
lar therapy can be applied to the clinic. Notably, the 
development of accurate tumour-specific delivery is a 
key hurdle to overcome to ensure the success of these 
therapies.
Several signalling networks are disrupted by pro-
moter methylation and this mechanism is often respon-
sible for the silencing of multiple regulatory genes 
within the same tumour cell. Targeting promoter meth-
ylation might, therefore, be a good therapeutic strategy. 
Demethylating agents and DNA methyltransferase 
inhibitors such as azacitidine or decitabine induce global 
genomic demethylation and have been successfully used 
in the treatment of haematological neoplasias such as 
acute myeloid leukaemia and chronic myelomonocytic 
leukaemia7. A preclinical assessment showed that fairly 
low doses of decitabine consistently reduced prolifer-
ation in15 RCC cell lines246 and several clinical trials 
are ongoing to determine the efficacy of such treat-
ments in solid tumours247,248. However, no large-scale 
trial for demethylation treatment in RCC is currently 
underway. Trials of HDAC inhibitors in patients with 
advanced RCC are currently underway249–251. HDAC 
inhibitors might be particularly effective in patients 
with BAP1 mutations as, in addition to reversing gene 
silencing initiated by aberrant promoter methylation, 
HDAC inhibitors might also have the ability to reverse 
H2A ubiquitylation, which is associated with loss of 
BAP1 (REF. 250). The identification of mutations in his-
tone-modifying enzymes such as BAP1 and PBRM1, 
which modulate multiple cell signalling pathways (for 
example mTOR, p53 and pRB–E2F) that are commonly 
dysregulated in RCC, provides the opportunity for the 
development of novel therapies. These new treatments 
might simultaneously interfere with multiple onco-
genic signalling pathways. Moreover, the characteriza-
tion of mutations and epigenetic marks in these genes, 
combined with the identification of specific epigenetic 
biomarkers of RCC, will inform future therapeutic devel-
opment and personalized treatment for renal cancers.
Conclusions
The study of renal cancer biology over the past 15 years 
has identified a central role for altered epigenetic control 
of gene expression in tumour development and progres-
sion. We anticipate that, with the development of increas-
ingly detailed analysis tools such as methylation-specific 
microarrays, epigenome sequencing and RNA sequenc-
ing, the integrated analysis of epigenetic regulatory 
networks will elucidate novel, clinically targetable mech-
anisms of RCC development. Such mechanistic advances 
will, hopefully, improve patient outcomes.
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 000 The epigenetic landscape of renal cancer
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New data suggests that, in addition to mutations in 
tumour-suppressor genes, renal cancer is associated 
with epigenetic aberrations. Here, the authors discuss 
the mechanisms by which epigenetically silenced 
genes and mutations in genes that are involved 
in histone modification or chromatin remodelling 
dysregulate crucial cellular pathways in renal cancer.
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